FOLD Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 116912 min ago

@ $13.20

Wydano: 14 vas. 2024 @ 22:36

Zwrot: -21.21%

Poprzedni sygnał: vas. 14 - 16:30

Poprzedni sygnał: Sprzedaż

Zwrot: 1.62 %

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	1.38M
Średni wolumen	3.06M
Kapitalizacja rynkowa	3.08B
EPS	$0 ( 2024-02-28 )
Następna data zysków	( $-0.0600 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-20.39
ATR14	$0.00900 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Campbell Bradley L	Buy	7 500	Common Stock
2024-05-01	Campbell Bradley L	Sell	7 500	Common Stock
2024-05-01	Campbell Bradley L	Sell	7 500	Stock Options (right to buy)
2024-04-15	Prout Samantha	Sell	7 027	Common Stock
2024-04-01	Campbell Bradley L	Buy	7 500	Common Stock

INSIDER POWER
17.18
Last 100 transactions
Buy: 1 721 174 \| Sell: 1 181 964

Wolumen Korelacja

Długi: -0.29 (neutral)

Krótki: -0.97 (very strong negative)

Signal:(44.39) Neutral

Amicus Therapeutics Inc Korelacja

10 Najbardziej pozytywne korelacje
SHLS	0.913
NVEE	0.903
SHC	0.899
MLCO	0.898
FULC	0.898
ALGT	0.894
SIBN	0.893
ARKO	0.887
MLTX	0.886
LPRO	0.88

10 Najbardziej negatywne korelacje
HZNP	-0.851
TLMD	-0.848
RXDX	-0.845
KNTK	-0.842
TRMR	-0.838
VITL	-0.837
STAA	-0.837
ENTX	-0.837
AEYE	-0.835
VTVT	-0.834

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Amicus Therapeutics Inc Korelacja - Waluta/Towar

0.62
( weak )

0.51
( weak )

0.00
( neutral )

0.88
( strong )

-0.71
( moderate negative )

Amicus Therapeutics Inc Finanse

Annual	2023
Przychody:	$399.36M
Zysk brutto:	$354.16M (88.68 %)
EPS:	$-0.510

FY	2023
Przychody:	$399.36M
Zysk brutto:	$354.16M (88.68 %)
EPS:	$-0.510

FY	2022
Przychody:	$329.23M
Zysk brutto:	$290.63M (88.28 %)
EPS:	$-0.820

FY	2021
Przychody:	$305.51M
Zysk brutto:	$271.05M (88.72 %)
EPS:	$-0.920

Financial Reports:

No articles found.

Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Aktualne aktualizacje dla Amicus Therapeutics Inc [FOLD]

Upcoming Earnings Alert